Category: Histogenics Corp.Syndicate content

Veran medical adds former Stryker CFO Hartman to board | Personnel Moves

November 21, 2013 by Chris Walker

Veran Medical Technologies appoints former Stryker CFO Curt Hartman as a member of its board of directors.

fired/hired

Veran Medical Technologies said it has brought in former Stryker (NYSE:SYK) CFO Curt Hartman to join its board of directors.

Histogenics appoints a new CEO | Personnel Moves

June 11, 2013 by Sony Salzman

Former Histogenics CEO Patrick O'Donnell is replaced by AstraZeneca veteran Peter Greenleaf as the company's orthopedic NeoCart device inches closer to commercialization.

fired/hired

Histogenics has a new face in the corner office with the appointment of Peter Greenleaf, an AstraZeneca veteran favored by the board for his experience moving products toward commercialization.

The company has its eyes on an end-stage pivotal trial for NeoCart, a device that uses patients' own cells to regenerate knee cartilage.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

UPDATE: Histogenics CEO on $49M funding round

July 24, 2012 by MassDevice staff

Histogenics CEO Patrick O'Donnell tells MassDevice.com that the regenerative medicine company plans to use the $49 million it just raised to fund a Phase III trial of its NeoCart regenerative knee cartilage treatment.

Histogenics

Histogenics said it raised another $49 million for its regenerative cartilage treatments, as it proceeds with a clinical trial for its NeoCart treatment and pursues CE Mark approval for its VeriCart system.

The round was led by Sofinnova Ventures and including backing from new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund. Prior backers ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also kicked in.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Histogenics drums up $49M for NeoCart trial

July 24, 2012 by MassDevice staff

Histogenics raises $49 million to fund a Phase III trial of its NeoCart regenerative knee cartilage treatment and get CE Mark approval for its VeriCart knee treatment in the European Union.

Histogenics

Histogenics said it raised another $49 million for its regenerative cartilage treatments, as it proceeds with a clinical trial for its NeoCart treatment and pursues CE Mark approval for its VeriCart system.

The round was led by Sofinnova Ventures and including backing from new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund. Prior backers ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also kicked in.

Whistleblowing doctor fired from Northwestern University | Personnel Moves

October 12, 2011 by MassDevice staff

Dr. Nalini Rajamannan, who sparked a federal investigation into fellow physician and inventor of the Myxo annuloplasty ring for allegedly implanting the device in patients without consent, is fired from Northwestern University after being denied tenure.

Dr. Nalini Rajamannan

A Northwestern University cardiologist who sparked a federal investigation into a fellow physician for alleged misconduct was fired after being denied tenure.

Dr. Nalini Rajamannan, who was an associate professor of medicine at the university, believes she was fired for providing evidence to federal investigators and for challenging the university's star surgeon.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

DeVivo takes over the corner office at AngioDynamics | Personnel Moves

September 13, 2011 by MassDevice staff

AngioDynamics names Joseph DeVivo as its new CEO, replacing Jan Keltjens, and reveals the departure of one of its senior business development executives.

AngioDynamics

AngioDynamics Inc. (NSDQ:ANGO) named a replacement for former CEO Jan Keltjens, who left suddenly in June, tapping Joseph DeVivo for the corner office.

The Latham, N.Y.-based oncology device company also revealed the resignation of senior vice president of business development Lynda Wallace, according to SEC filings.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Histogenics hires Dr. Michael Lewis and Peter Hamiltion to lead NeoCart in Phase III

September 13, 2011 by MassDevice

Source: 
Business Wire Health: Clinical Trials News

WALTHAM, Mass.--(BUSINESS WIRE)--Regenerative medicine company Histogenics Corporation appoints Michael Lewis, M.D. to CMO and Peter Hamilton to VP of Manufacturing & Production to support Phase 3 development of NeoCart.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp